选择性上腺素再吸收抑制作为人类的正静性不耐受性模型
Christoph Schroeder1, Jens Tank, Michael Boschmann
1Clinical Research Center, HELIOS Klinkum-Berlin, Germany. jordan@fvk-berlin.de
Circulation
|January 24, 2002
概括
阻断诺拉上腺素转运体 (NET) 功能与reboxetine模仿了健康受试者的异常性静态不耐受性. 这表明受损的上腺素吸收有助于心血管疾病,并可能有助于预防血管反应.
科学领域:
- 心血管生理学心血管生理学
- 神经药理学神经药理学
背景情况:
- 上腺素载体 (NET) 基因的功能性突变与异常性静止不耐症有关.
- 受损的北上腺素再吸收是导致这种情况的潜在因素.
研究的目的:
- 在健康个体中,研究选择性阻断北上腺素输送体 (NET) 的心血管影响.
- 为了确定NET阻塞是否复制了特异性静态不耐受症的表型.
主要方法:
- 一项随机,双盲,交叉研究,涉及18名健康受试者.
- 选择性NET阻断剂 (reboxetine) 或安慰剂的使用.
- 在冷压力测试,手握测试和头向上倾斜测试 (HUT) 中评估心血管反应.
主要成果:
- 与安慰剂相比,reboxetine在HUT期间显著增加了心率 (P<0.0001).
- 随着reboxetine的使用,平均动脉压略有升高,但对压力测试的血压反应减弱.
- 雷博克塞丁增强了对异二醇和烯酸的敏感性,并减少了血管反应.
结论:
- 选择性NET阻塞会诱导一种类似于异常性静态不耐症的心血管现象型.
- 这支持了一个假设,即乱的北上腺素再吸收有助于人类心血管疾病.
- NET抑制可能是预防血管血管反应的潜在策略.
相关概念视频
Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...


